Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of H56:IC31 for prevention of Mycobacterium tuberculosis infection in healthy adolescents
PACTR201704002006214Phase 2Not yet recruiting
- Sponsor
- Aeras Global Vaccine Foundation
- Start
- Jun 2017
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in Tuberculosis (TB) comparing H56:IC31 with Placebo (2 arms). Planned start Jun 2017; status: not yet recruiting.
02
Drugs
AERAS-456
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on PACTR201704002006214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201704002006214.